Skip to main content

Table 1 Baseline characteristics

From: Choline-stabilized orthosilicic acid supplementation as an adjunct to Calcium/Vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial

 

Placebo

ch-OSA

  

3 mg Si

6 mg Si

12 mg Si

AGE (years)

62.0 ± 10.9 (n = 37)

60.4 ± 11.8 (n = 33)

59.7 ± 9.4 (n = 33)

60.8 ± 9.7 (n = 33)

BMI

23.2 ± 3.0 (n = 37)

24.4 ± 3.8 (n = 33)

24.1 ± 4.6 (n = 33)

25.2 ± 3.8 (n = 33)

Menopausal status

6 pre/31 post (n = 37)

6 pre/27 post (n = 33)

5 pre/28 post (n = 33)

4 pre/29 post (n = 33)

BMD

    

Spine total (g/cm 2 )

0.797 ± 0.061 (n = 37)

0.805 ± 0.052 (n = 33)

0.805 ± 0.069 (n = 33)

0.776 ± 0.072b (n = 33)

Femur total (g/cm 2 )

0.789 ± 0.103 (n = 37)

0.791 ± 0.094 (n = 33)

0.792 ± 0.080 (n = 33)

0.781 ± 0.103 (n = 33)

Femur neck (g/cm 2 )

0.670 ± 0.085 (n = 37)

0.677 ± 0.085 (n = 33)

0.667 ± 0.079 (n = 33)

0.649 ± 0.084 (n = 33)

BONEMARKERS

    

OC (ng/ml)

9.74 ± 3.16 (n = 31)

10.17 ± 3.91 (n = 27)

10.65 ± 3.32 (n = 27)

10.16 ± 3.67 (n = 25)

BAP (U/L)

21.65 ± 6.30 (n = 32)

20.43 ± 7.24 (n = 26)

21.85 ± 6.31 (n = 27)

21.58 ± 7.36 (n = 27)

PINP (μg/L)

47.20 ± 13.45 (n = 30)

46.28 ± 21.46 (n = 26)

44.78 ± 16.07 (n = 28)

48.77 ± 15.09 (n = 30)

DPD (/Cr)

5.57 ± 3.12 (n = 28)

5.22 ± 1.50 (n = 26)

5.74 ± 1.45 (n = 27)

5.92 ± 1.57a (n = 28)

CTX-I (μg/mmol Cr)

359.01 ± 129.89 (n = 31)

331.88 ± 155.87 (n = 26)

349.10 ± 126.71 (n = 27)

360.43 ± 139.00 (n = 28)

  1. Baseline characteristics of patients (n = 136), mean ± SD, a: p < 0.05 (unpaired t-test) versus placebo, b: p < 0.05 (unpaired t-test) versus 3 mg Si.
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us